Pixuvri’s Conditional EU Approval Could Herald The Rise Of Staggered Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
CTI’s conditional EU approval for its non-Hodgkin B-cell lymphoma drug Pixuvri goes against the run of the drug in the US, but reinforces the idea that staggered approvals are on the way in Europe.
You may also be interested in...
Rare EMA-Sanctioned Compassionate Use Program Sends Gilead’s Sofosbuvir To Market Early
Gilead Sciences sofosbuvir for hepatitis C has gained early, but restricted, entry into the EU market as the European Medicines Agency allows compassionate use at Sweden’s request.
CTI’s Pixuvri Flops Again At British NICE, As Discount Fails To Impress
Despite a sizeable price cut, uncertainty surrounding CTI’s non-Hodgkin’s lymphoma therapy Pixuvri has landed it with a second NICE rejection.
Germany’s G-BA Finds No Added Benefit For CTI’s Pixuvri, Exposing Price
Germany’s G-BA lets through Cell Therapeutics’ Pixuvri for aggressive B-cell non-Hodgkin's lymphoma but finds no added benefit over existing therapies, meaning its price could come under pressure.